BioNTech CEO confident vaccine will work on UK variant
The chief executive of BioNTech says the German pharmaceutical company is confident that its coronavirus vaccine works against the UK variant, but further studies are need to be completely sure
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.German pharmaceutical company BioNTech is confident that its coronavirus vaccine works against the new UK variant, but further studies are need to be completely sure, its chief executive said Tuesday.
The variant, detected mainly in London and the southeast of England in recent weeks, has sparked concern worldwide because of signs that it may spread more easily. While there is no indication it causes more serious illness, numerous countries in Europe and beyond have restricted travel from the UK as a result.
“We don’t know at the moment if our vaccine is also able to provide protection against this new variant,” Ugur Sahin told a news conference the day after the vaccine was approved for use in the European Union. “But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants.”
Sahin said that the proteins on the UK variant are 99% the same as on the prevailing strains, and therefore BioNTech has “scientific confidence” that its vaccine will be effective.
“But we will know it only if the experiment is done and we will need about two weeks from now to get the data,” he said. “The likelihood that our vaccine works ... is relatively high."
Should the vaccine need to be adjusted for the new variant the company could do so in about 6 weeks, said Ugur, though regulators might have to approve the changes before the shots can be used.
BioNTech’s vaccine, developed together with U.S. pharmaceutical company Pfizer, is authorized for use in more than 45 countries including Britain, the United States and the EU.
___
Follow AP’s pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak